Skip to main content

Jonah Comstock

By Jonah Comstock | 09:17 am | March 18, 2015
Pharma-focused mobile clinical trial data collection company Clinical Ink has merged with CentrosHealth, formerly MyHealthBook, which makes configurable mobile apps for clinical trial patient engagement.
By Jonah Comstock | 02:00 am | March 18, 2015
San Francisco-based Conversa Health, which makes a digital patient engagement platform, has raised $2.
By Jonah Comstock | 10:48 am | March 17, 2015
Great Lakes NeuroTechnologies, which makes mobile software and wearable devices for monitoring symptoms of Parkinson's disease, has released a new clinical version of its technology that supports continuous monitoring.
By Jonah Comstock | 10:08 am | March 17, 2015
The Project Emerge app at Johns Hopkins.
By Jonah Comstock | 08:06 am | March 17, 2015
OptimizeMe, the Zurich, Switzerland-based life logging app that interprets wellness data users collect through apps and devices, will soon launch its second version under a new name, following an "amicable legal dispute resolution" with UnitedHealth Group.
By Jonah Comstock | 05:32 am | March 17, 2015
Diabetes management platform Glooko has raised $16.
By Jonah Comstock | 09:42 am | January 30, 2015
The past few weeks have been good to digital health projects on crowdfunding platforms Indiegogo and Kickstarter.
By Jonah Comstock | 08:44 am | January 29, 2015
Less than a month after announcing its partnership with Novartis, Qualcomm is adding another big pharmaceutical company to its list of 2net partners: Roche, who will use Qualcomm Life's 2net platform to capture patient data from connected devices, starting with anti-coagulation meters.
By Jonah Comstock | 08:32 am | January 29, 2015
Toumaz, a developer of low-power wireless systems, made $1.
By Jonah Comstock | 05:02 am | January 29, 2015
AliveCor's AF detection algorithm San Francisco-based AliveCor has received FDA clearance for two new algorithms for its smartphone-connected ECG: one that detects normality and one that detects interference.